Intocostrin, 5cc, 100 Units, (A Physiologically Standardized preparation from Curare)

Description:

The indications or use of this product as provided by the manufacturer are: Clinical investigation indicates Intocostrin can be used to supplement anesthetic agents, inducing a muscular relaxation which facilitates surgery. When given intravenously immediately before the shock therapy of mental disease, it is useful in softening the severity of convulsions and preventing fractures. It produces a more or less transient but often useful relaxing effect in certain neurologic conditions. It may be useful for its relaxing effect in carrying out certain manipulative diagnostic procedures as well as in the reduction of fractures or dislocations. The specific action of curare is useful in the diagnosis of myasthenia gravis. [from paper insert]

Yellow paper-covered cardboard box with yellow and brown label. Box contains one glass vial with rubber and metal stopper and paper label, and one paper insert. Vial is about 60% full of brownish liquid. List 4854; Lot No. 0090320.

In 1939 E. R Squibb & Sons introduced Intocostrine, the first commercially available preparation of curare for clinical use. The drug is an extract of the South American vine Chondrodendron tomentosum, one of the principal sources of curare. The active alkaloid, d-tubocurarine chloride, was isolated in crystalline form in the mid-1930s.